The $1.4bn deal will combine Invitae’s centralized laboratory capabilities with ArcherDX’s precision oncology technologies.
Invitae Corp. will acquire ArcherDX Inc. for $1.4bn to create a single cancer diagnostics "platform" combining hereditary testing, tumor profiling, liquid biopsy technologies and genetic testing services.
Invitae is a San Francisco-based medical genetics company focused on aggregating genetic testing information into a single service to increase...
Create an account to read this article
Already a subscriber?
Barcelona-based INBRAIN Neuroelectronics is partnering with Mayo Clinic to test whether its graphene-based cortical brain computer interface can enhance standard DBS in Parkinson’s, aiming for more precise adaptive therapy and improved gait outcomes.
SafeHeal has secured an additional €10m for its Colovac device, bringing its total funding to €97.5m. Led by Asabys Partners, this funding offers both economic and clinical benefits, potentially reducing costs and complications associated with temporary stomas.
An interactive look at medtech and diagnostics deals made during August 2025. Data courtesy of Biomedtracker.
Roche’s scanners have been integrated with PathAI’s AISight Dx system. The system’s FDA-cleared PCCP allows new components to be validated and integrated without additional FDA clearance. Eric Walk, chief medical officer, hints at future biopharma companion diagnostic collaborations.
After receiving US FDA clearance and reporting first successful use at Mayo Clinic, the Silicon Valley start-up plans to partner with leading centers to transform needle-based procedures with its robotic system starting with urology, then expand into other specialties, the CEO said.
SafeHeal has secured an additional €10m for its Colovac device, bringing its total funding to €97.5m. Led by Asabys Partners, this funding offers both economic and clinical benefits, potentially reducing costs and complications associated with temporary stomas.
Galvanize will use its $100m Series C funding to expand commercial operations and advance Aliya PEF in oncology and RheOx in chronic bronchitis, while continuing to refine its nonthermal PEF platform, which delivers short electrical pulses to disrupt disease processes.
